We aimed to support our hypothesis by comparing the qualitative and quantitative data from this survey with a 'best practice model' of pathology teaching found at SOM after its modernization.
We present this automated slice system as an appropriate model of in vivo remyelination in the rodent CNS, and as a model of pathology in MS. We suggest that it can be used as an intermediate step between in vitro experiments and undertaking lengthy in vivo studies, to select the most promising compounds, though clearly not replacing the latter.
The single-pot antibody library PHILOtop may thus represent a useful source of binding specificities, facilitating preclinical studies in immunocompetent syngeneic mouse models of pathology.
Over the past several decades, work in neuroscience, psychiatry, psychology, and biology have uncovered key processes underlying, and structures governing, emotional responding and learning, as well as identified disruptions in the structural and functional integrity of these brain regions in models of pathology.
Novel proteomic technologies derived from terminal perfusion of mouse models of pathology with biotinylation reagents, followed by a mass spectrometry-based comparative analysis, might be used in the future for the discovery of novel accessible markers of arthritis [ 54, 55].
In order to study osteoarthritis (OA) in both man and animals, much use has been made of animal models of pathology to generate consistent, reproducible articular cartilage lesions within a relatively rapid period of time [ 1].
Whilst animal models of pathology have provided researchers with a wealth of knowledge about events that occur in joint disease, there are drawbacks to their use including the difficulty of isolating different tissue responses to a given insult.
To develop one, a promising strategy is the use of models of pathologies that are characterized by autistic features [2].
No animal models of autism spectrum disorders (ASD) with good construct validity are currently available; using genetic models of pathologies characterized by ASD-like deficits, but with known causes, may be therefore a promising strategy.
The need for animal models of pathologies affecting the central nervous system has been recognized since 1980 [ 4].
One of these compounds, the mitochondria-targeted antioxidant mitoquinone (MitoQ), has shown efficacy in a number of animal models of pathologies [26 32].
